Ionis Pharmaceuticals (LTS:0JDI) Net Change in Cash : $39.9 Mil (TTM As of Mar. 2024)

View and export this data going back to 1991. Start your Free Trial

What is Ionis Pharmaceuticals Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Ionis Pharmaceuticals's Net Change in Cash for the three months ended in Mar. 2024 was $-50.4 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was $39.9 Mil.

Ionis Pharmaceuticals Net Change in Cash Historical Data

The historical data trend for Ionis Pharmaceuticals's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals Net Change in Cash Chart

Ionis Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

Get a 7-Day Free Trial

404.47

-285.62

471.53

-592.72

122.79

Ionis Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Change in Cash	Get a 7-Day Free Trial															32.56	115.76	-72.73	47.21	-50.38

Ionis Pharmaceuticals Net Change in Cash Calculation

Ionis Pharmaceuticals's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-307.513	+	-214.127	+	644.082	+	0.352
	=	122.8

Ionis Pharmaceuticals's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -149.938 + 76.105 + 23.57 + -0.114

= -50.4

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $39.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Ionis Pharmaceuticals's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Ionis Pharmaceuticals (LTS:0JDI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (LTS:0JDI) » Definitions » Net Change in Cash

Comparable Companies

APLS RVMD BPMC PCVX JAZZ CYTK EXEL IBRX HALO BBIO OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX

Traded in Other Exchanges

IONS:USA IONS:Mexico ISI:Germany

Address

2855 Gazelle Court, Carlsbad, CA, USA, 92010

Website

https://www.ionispharma.com

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Ionis Pharmaceuticals (LTS:0JDI) Headlines

No Headlines